Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Blood (2025) 146 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2025-4498

Published: 2025

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 565.

https://doi.org/10.1182/blood-2025-565

Published: 2025

Journal Articles

Risk stratification based on machine learning for severe cytokine release syndrome in RRMM patients treated with bispecific antibodies

Roberto Mancebo-Martin, Magdalena Corona De Lapuerta, Lara Rodriguez-Luque, Cristian Gutiérrez Padilla, David Bermejo-Peláez, Nuria Diez Navarro, David Brau-Queralt, Nieves Lopez Muñoz, Rafael Alonso Fernandez, Jose Maria Sanchez Pina, Miguel Luengo-Oroz, Joaquin Martinez Lopez

Blood (2025) 146 (Supplement 1): 6349.

https://doi.org/10.1182/blood-2025-6349

Published: 2025

Journal Articles

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

Maria Sanchez-Tabernero, Magdalena Corona, Cristian Gutiérrez Padilla, Jose Sanchez-Pina, Rafael Alonso, Inmaculada Rapado, Nieves Lopez-Muñoz, Gonzalo Carreño, Susana Cortijo, Maria Teresa Cedena Romero, Manuela Fernández, Rosa Ayala Diaz, Maria Calbacho, Joaquin Martinez-Lopez

Blood (2025) 146 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2025-5781

Published: 2025

Journal Articles

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Blood (2025) 146 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2025-2710

Published: 2025

Journal Articles

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Blood (2025) 146 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2025-5341

Published: 2025

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Blood (2024) 144 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2024-201029

Published: 2024

Journal Articles

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3752.

https://doi.org/10.1182/blood-2024-211475

Published: 2024

Journal Articles

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Murali Janakiram, Carlyn Rose Tan, Rakesh Popat, Joaquín Martínez Lopez, Efstathios Kastritis, Chris Lau, Wee-Joo Chng, Prashant Kapoor, Hira Mian, Susan Bal, Ajay K. Nooka, Andre De Menezes Silva Corraes, Magdalena Corona, Arnab Chowdhury, Yi Lin, Thomas G Martin, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2024-211167

Published: 2024

Journal Articles

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Blood (2024) 144 (Supplement 1): 5166.

https://doi.org/10.1182/blood-2024-210518

Published: 2024

Journal Articles

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Blood (2024) 144 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2024-203871

Published: 2024

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Blood (2024) 144 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2024-205548

Published: 2024

Journal Articles

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Blood (2024) 144 (Supplement 1): 4509.

https://doi.org/10.1182/blood-2024-212274

Published: 2024

Journal Articles

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4889.

https://doi.org/10.1182/blood-2023-187240

Published: 2023

Journal Articles

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Giulio Cassanello, Efrat Luttwak, Sean M. Devlin, Alejandro Luna De Abia, Magdalena Corona, Ivan Landego, Allison Parascondola, Amethyst Saldia, Ana Alarcon Tomas, Parastoo B. Dahi, Richard J. Lin, M. Lia Palomba, Jae H. Park, Gilles Salles, Miguel-Angel Perales, Michael Scordo, Roni Shouval, Gunjan L. Shah

Blood (2023) 142 (Supplement 1): 6898.

https://doi.org/10.1182/blood-2023-190500

Published: 2023

Journal Articles

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Blood (2023) 142 (Supplement 1): 6907.

https://doi.org/10.1182/blood-2023-181999

Published: 2023

Journal Articles

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Blood (2023) 142 (Supplement 1): 7156.

https://doi.org/10.1182/blood-2023-190332

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Risk stratification based on machine learning for severe cytokine release syndrome in RRMM patients treated with bispecific antibodies

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only